BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9413152)

  • 1. Oncogene and HSP-70 expression in primary tumor cell cultures of renal cell carcinoma compared to their corresponding cell line.
    Köhler G; Veelken H; Rosenthal F; Mackensen A; Lindemann A; Schaefer HE; Lahn M
    Anticancer Res; 1997; 17(5A):3225-31. PubMed ID: 9413152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.
    Weidner U; Peter S; Strohmeyer T; Hussnätter R; Ackermann R; Sies H
    Cancer Res; 1990 Aug; 50(15):4504-9. PubMed ID: 1973362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
    Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
    Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.
    Bilim V; Kawasaki T; Katagiri A; Wakatsuki S; Takahashi K; Tomita Y
    Clin Cancer Res; 2000 Feb; 6(2):460-6. PubMed ID: 10690524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased glyceraldehyde-3-phosphate dehydrogenase expression in renal cell carcinoma identified by RNA-based, arbitrarily primed polymerase chain reaction.
    Vilà MR; Nicolás A; Morote J; de I; Meseguer A
    Cancer; 2000 Jul; 89(1):152-64. PubMed ID: 10897012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
    Sejima T; Miyagawa I
    Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of BHD in sporadic renal tumors.
    Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
    Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
    Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
    Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
    Allory Y; Matsuoka Y; Bazille C; Christensen EI; Ronco P; Debiec H
    Clin Cancer Res; 2005 Feb; 11(3):1190-7. PubMed ID: 15709188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
    Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
    Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
    Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
    Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).
    Bilim VN; Kawasaki T; Takahashi K; Tomita Y
    Anticancer Res; 1998; 18(3A):1655-9. PubMed ID: 9673385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of chromosomes in clear cell renal cell carcinoma and in corresponding renal parenchyma.
    Feil G; Leipoldt M; Nelde HJ; Wunderer A; Wechsel HW; Kaiser P; Bichler KH
    Anticancer Res; 1999; 19(2C):1477-82. PubMed ID: 10365127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
    Hollmann CA; Kittrell FS; Medina D; Butel JS
    Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and co-expression of cellular oncogenes in the course of tumor progression in neuroendocrine lung tumors].
    Kogan EA; Shtabskiĭ AB; Sekamova SM; Sukhova NM; Mazurenko NN
    Arkh Patol; 1994; 56(2):16-21. PubMed ID: 8037585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model.
    Weber KL; Pathak S; Multani AS; Price JE
    J Urol; 2002 Aug; 168(2):774-9. PubMed ID: 12131367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues.
    Perego RA; Bianchi C; Corizzato M; Eroini B; Torsello B; Valsecchi C; Di Fonzo A; Cordani N; Favini P; Ferrero S; Pitto M; Sarto C; Magni F; Rocco F; Mocarelli P
    J Proteome Res; 2005; 4(5):1503-10. PubMed ID: 16212400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
    Volm M; Kästel M; Mattern J; Efferth T
    Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
    Rodins K; Cheale M; Coleman N; Fox SB
    Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.